Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. Hospitals

Ellen Smith Moland, Jennifer A. Black, Jason Ourada, Mark Reisbig, Nancy D. Hanson, Kenneth S. Thomson

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Despite the discovery of novel β-lactamases such as extended-spectrum β-lactamases (ESBLs), imported AmpC, and carbapenem-hydrolyzing β-lactamases at least a decade ago, there remains a low level of awareness of their importance and how to detect them. There is a need to increase the levels of awareness of clinical laboratories about the detection of newer β-lactamases. Therefore, a study was conducted in 2000 to investigate the occurrence of these β-lactamases in Klebsiella pneumoniae isolates at 24 U.S. medical centers. To enhance the likelihood of detecting imported AmpC and carbapenem-hydrolyzing β-lactamases, participating laboratories were permitted to include archived strains (1996 to 2000) that were intermediate or resistant to either cefoxitin or imipenem. The β-lactamase production of 408 isolates positive by screening of 1,123 isolates was investigated by ESBL phenotypic confirmation tests; and for AmpC and carbapenem-hydrolyzing β-lactamases, three-dimensional tests, isoelectric focusing, β-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular tests were used. ESBL-producing isolates were detected at 18 of the 24 sites (75%), imported AmpC-producing isolates were detected at 10 sites (42%), inducible imported AmpC-producing isolates were detected at 3 sites (12.5%), and a molecular class A carbapenem-hydrolyzing enzyme was detected at 1 site (4%). No class B or D carbapenem-hydrolyzing enzymes were detected. ESBLs and imported AmpC β-lactamases were detected at a significant number of sites, indicating widespread penetration of these enzymes into U.S. medical institutions. Because these enzymes may significantly affect therapeutic outcomes, it is vital that clinical laboratories be aware of them and be able to detect their occurrence.

Original languageEnglish
Pages (from-to)3837-3842
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume46
Issue number12
DOIs
StatePublished - Dec 1 2002

Fingerprint

Carbapenems
Klebsiella pneumoniae
Enzymes
Cefoxitin
Imipenem
Isoelectric Focusing

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. Hospitals. / Moland, Ellen Smith; Black, Jennifer A.; Ourada, Jason; Reisbig, Mark; Hanson, Nancy D.; Thomson, Kenneth S.

In: Antimicrobial Agents and Chemotherapy, Vol. 46, No. 12, 01.12.2002, p. 3837-3842.

Research output: Contribution to journalArticle

Moland, Ellen Smith ; Black, Jennifer A. ; Ourada, Jason ; Reisbig, Mark ; Hanson, Nancy D. ; Thomson, Kenneth S. / Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. Hospitals. In: Antimicrobial Agents and Chemotherapy. 2002 ; Vol. 46, No. 12. pp. 3837-3842.
@article{f9bc4ae99bc047778a79be11c8ca2d73,
title = "Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. Hospitals",
abstract = "Despite the discovery of novel β-lactamases such as extended-spectrum β-lactamases (ESBLs), imported AmpC, and carbapenem-hydrolyzing β-lactamases at least a decade ago, there remains a low level of awareness of their importance and how to detect them. There is a need to increase the levels of awareness of clinical laboratories about the detection of newer β-lactamases. Therefore, a study was conducted in 2000 to investigate the occurrence of these β-lactamases in Klebsiella pneumoniae isolates at 24 U.S. medical centers. To enhance the likelihood of detecting imported AmpC and carbapenem-hydrolyzing β-lactamases, participating laboratories were permitted to include archived strains (1996 to 2000) that were intermediate or resistant to either cefoxitin or imipenem. The β-lactamase production of 408 isolates positive by screening of 1,123 isolates was investigated by ESBL phenotypic confirmation tests; and for AmpC and carbapenem-hydrolyzing β-lactamases, three-dimensional tests, isoelectric focusing, β-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular tests were used. ESBL-producing isolates were detected at 18 of the 24 sites (75{\%}), imported AmpC-producing isolates were detected at 10 sites (42{\%}), inducible imported AmpC-producing isolates were detected at 3 sites (12.5{\%}), and a molecular class A carbapenem-hydrolyzing enzyme was detected at 1 site (4{\%}). No class B or D carbapenem-hydrolyzing enzymes were detected. ESBLs and imported AmpC β-lactamases were detected at a significant number of sites, indicating widespread penetration of these enzymes into U.S. medical institutions. Because these enzymes may significantly affect therapeutic outcomes, it is vital that clinical laboratories be aware of them and be able to detect their occurrence.",
author = "Moland, {Ellen Smith} and Black, {Jennifer A.} and Jason Ourada and Mark Reisbig and Hanson, {Nancy D.} and Thomson, {Kenneth S.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1128/AAC.46.12.3837-3842.2002",
language = "English",
volume = "46",
pages = "3837--3842",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 U.S. Hospitals

AU - Moland, Ellen Smith

AU - Black, Jennifer A.

AU - Ourada, Jason

AU - Reisbig, Mark

AU - Hanson, Nancy D.

AU - Thomson, Kenneth S.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Despite the discovery of novel β-lactamases such as extended-spectrum β-lactamases (ESBLs), imported AmpC, and carbapenem-hydrolyzing β-lactamases at least a decade ago, there remains a low level of awareness of their importance and how to detect them. There is a need to increase the levels of awareness of clinical laboratories about the detection of newer β-lactamases. Therefore, a study was conducted in 2000 to investigate the occurrence of these β-lactamases in Klebsiella pneumoniae isolates at 24 U.S. medical centers. To enhance the likelihood of detecting imported AmpC and carbapenem-hydrolyzing β-lactamases, participating laboratories were permitted to include archived strains (1996 to 2000) that were intermediate or resistant to either cefoxitin or imipenem. The β-lactamase production of 408 isolates positive by screening of 1,123 isolates was investigated by ESBL phenotypic confirmation tests; and for AmpC and carbapenem-hydrolyzing β-lactamases, three-dimensional tests, isoelectric focusing, β-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular tests were used. ESBL-producing isolates were detected at 18 of the 24 sites (75%), imported AmpC-producing isolates were detected at 10 sites (42%), inducible imported AmpC-producing isolates were detected at 3 sites (12.5%), and a molecular class A carbapenem-hydrolyzing enzyme was detected at 1 site (4%). No class B or D carbapenem-hydrolyzing enzymes were detected. ESBLs and imported AmpC β-lactamases were detected at a significant number of sites, indicating widespread penetration of these enzymes into U.S. medical institutions. Because these enzymes may significantly affect therapeutic outcomes, it is vital that clinical laboratories be aware of them and be able to detect their occurrence.

AB - Despite the discovery of novel β-lactamases such as extended-spectrum β-lactamases (ESBLs), imported AmpC, and carbapenem-hydrolyzing β-lactamases at least a decade ago, there remains a low level of awareness of their importance and how to detect them. There is a need to increase the levels of awareness of clinical laboratories about the detection of newer β-lactamases. Therefore, a study was conducted in 2000 to investigate the occurrence of these β-lactamases in Klebsiella pneumoniae isolates at 24 U.S. medical centers. To enhance the likelihood of detecting imported AmpC and carbapenem-hydrolyzing β-lactamases, participating laboratories were permitted to include archived strains (1996 to 2000) that were intermediate or resistant to either cefoxitin or imipenem. The β-lactamase production of 408 isolates positive by screening of 1,123 isolates was investigated by ESBL phenotypic confirmation tests; and for AmpC and carbapenem-hydrolyzing β-lactamases, three-dimensional tests, isoelectric focusing, β-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular tests were used. ESBL-producing isolates were detected at 18 of the 24 sites (75%), imported AmpC-producing isolates were detected at 10 sites (42%), inducible imported AmpC-producing isolates were detected at 3 sites (12.5%), and a molecular class A carbapenem-hydrolyzing enzyme was detected at 1 site (4%). No class B or D carbapenem-hydrolyzing enzymes were detected. ESBLs and imported AmpC β-lactamases were detected at a significant number of sites, indicating widespread penetration of these enzymes into U.S. medical institutions. Because these enzymes may significantly affect therapeutic outcomes, it is vital that clinical laboratories be aware of them and be able to detect their occurrence.

UR - http://www.scopus.com/inward/record.url?scp=0036895367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036895367&partnerID=8YFLogxK

U2 - 10.1128/AAC.46.12.3837-3842.2002

DO - 10.1128/AAC.46.12.3837-3842.2002

M3 - Article

VL - 46

SP - 3837

EP - 3842

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -